A ribonucleoprotein octamer for targeted siRNA delivery
Hurdles in cell-specific delivery of small interfering RNA (siRNA) in vivo hinder the clinical translation of RNA interference (RNAi). A fundamental problem concerns conflicting requirements for the design of the delivery vehicles: cationic materials facilitate cargo condensation and endosomolysis,...
Gespeichert in:
Veröffentlicht in: | Nature biomedical engineering 2018-05, Vol.2 (5), p.326-337 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 337 |
---|---|
container_issue | 5 |
container_start_page | 326 |
container_title | Nature biomedical engineering |
container_volume | 2 |
creator | Tai, Wanyi Li, Junwei Corey, Eva Gao, Xiaohu |
description | Hurdles in cell-specific delivery of small interfering RNA (siRNA) in vivo hinder the clinical translation of RNA interference (RNAi). A fundamental problem concerns conflicting requirements for the design of the delivery vehicles: cationic materials facilitate cargo condensation and endosomolysis, yet hinder in vivo targeting and colloidal stability. Here, we describe a self-assembled, compact (~30 nm) and biocompatible ribonucleoprotein-octamer nanoparticle that achieves endosomal destabilization and targeted delivery. The protein octamer consists of a poly(ethylene glycol) scaffold, a sterically masked endosomolytic peptide and a double-stranded RNA-binding domain, providing a discrete number of siRNA loading sites and a high siRNA payload (>30 wt%), and offering flexibility in both siRNA and targeting-ligand selection. We show that a ribonucleoprotein octamer against the polo-like kinase 1 gene and bearing a ligand that binds to prostate-specific membrane antigen leads to efficient gene silencing in prostate tumour cells in vitro and when intravenously injected in mouse models of prostate cancer. The octamer's versatile nanocarrier design should offer opportunities for the clinical translation of therapies based on intracellularly acting biologics. |
doi_str_mv | 10.1038/s41551-018-0214-1 |
format | Article |
fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6136846</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>30936447</sourcerecordid><originalsourceid>FETCH-LOGICAL-p163t-3055b8786df9462de23ee36257ada9c9c8a73c1a0b0af72d83638397a0b70f0c3</originalsourceid><addsrcrecordid>eNpVkNtKAzEYhIMgttQ-gDeyLxBN9s_xRihFrVAURMG7JZv8WyPbzZLdFvr2FjygVwMzzAczhFxwdsUZmOtBcCk5ZdxQVnJB-QmZllxqaoR6m5D5MHwwxrgFYbU8IxNgFpQQekr0osixTt3Ot5j6nEaMXZH86LaYiyblYnR5gyOGYojPj4siYBv3mA_n5LRx7YDzb52R17vbl-WKrp_uH5aLNe25gpECk7I22qjQWKHKgCUggiqldsFZb71xGjx3rGau0WUwoMCA1UdDs4Z5mJGbL26_q7cYPHZjdm3V57h1-VAlF6v_SRffq03aV4qDOq4_Ai7_An6bPxfAJ9PQXhw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A ribonucleoprotein octamer for targeted siRNA delivery</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Tai, Wanyi ; Li, Junwei ; Corey, Eva ; Gao, Xiaohu</creator><creatorcontrib>Tai, Wanyi ; Li, Junwei ; Corey, Eva ; Gao, Xiaohu</creatorcontrib><description>Hurdles in cell-specific delivery of small interfering RNA (siRNA) in vivo hinder the clinical translation of RNA interference (RNAi). A fundamental problem concerns conflicting requirements for the design of the delivery vehicles: cationic materials facilitate cargo condensation and endosomolysis, yet hinder in vivo targeting and colloidal stability. Here, we describe a self-assembled, compact (~30 nm) and biocompatible ribonucleoprotein-octamer nanoparticle that achieves endosomal destabilization and targeted delivery. The protein octamer consists of a poly(ethylene glycol) scaffold, a sterically masked endosomolytic peptide and a double-stranded RNA-binding domain, providing a discrete number of siRNA loading sites and a high siRNA payload (>30 wt%), and offering flexibility in both siRNA and targeting-ligand selection. We show that a ribonucleoprotein octamer against the polo-like kinase 1 gene and bearing a ligand that binds to prostate-specific membrane antigen leads to efficient gene silencing in prostate tumour cells in vitro and when intravenously injected in mouse models of prostate cancer. The octamer's versatile nanocarrier design should offer opportunities for the clinical translation of therapies based on intracellularly acting biologics.</description><identifier>EISSN: 2157-846X</identifier><identifier>DOI: 10.1038/s41551-018-0214-1</identifier><identifier>PMID: 30936447</identifier><language>eng</language><publisher>England</publisher><subject>Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacokinetics ; Cell Line, Tumor ; Drug Delivery Systems - methods ; Gene Silencing ; Humans ; Polyethylene Glycols - chemistry ; Ribonucleoproteins - chemistry ; Ribonucleoproteins - pharmacokinetics ; RNA, Small Interfering - chemistry ; RNA, Small Interfering - genetics ; RNA, Small Interfering - pharmacokinetics</subject><ispartof>Nature biomedical engineering, 2018-05, Vol.2 (5), p.326-337</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-6054-0530</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30936447$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tai, Wanyi</creatorcontrib><creatorcontrib>Li, Junwei</creatorcontrib><creatorcontrib>Corey, Eva</creatorcontrib><creatorcontrib>Gao, Xiaohu</creatorcontrib><title>A ribonucleoprotein octamer for targeted siRNA delivery</title><title>Nature biomedical engineering</title><addtitle>Nat Biomed Eng</addtitle><description>Hurdles in cell-specific delivery of small interfering RNA (siRNA) in vivo hinder the clinical translation of RNA interference (RNAi). A fundamental problem concerns conflicting requirements for the design of the delivery vehicles: cationic materials facilitate cargo condensation and endosomolysis, yet hinder in vivo targeting and colloidal stability. Here, we describe a self-assembled, compact (~30 nm) and biocompatible ribonucleoprotein-octamer nanoparticle that achieves endosomal destabilization and targeted delivery. The protein octamer consists of a poly(ethylene glycol) scaffold, a sterically masked endosomolytic peptide and a double-stranded RNA-binding domain, providing a discrete number of siRNA loading sites and a high siRNA payload (>30 wt%), and offering flexibility in both siRNA and targeting-ligand selection. We show that a ribonucleoprotein octamer against the polo-like kinase 1 gene and bearing a ligand that binds to prostate-specific membrane antigen leads to efficient gene silencing in prostate tumour cells in vitro and when intravenously injected in mouse models of prostate cancer. The octamer's versatile nanocarrier design should offer opportunities for the clinical translation of therapies based on intracellularly acting biologics.</description><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacokinetics</subject><subject>Cell Line, Tumor</subject><subject>Drug Delivery Systems - methods</subject><subject>Gene Silencing</subject><subject>Humans</subject><subject>Polyethylene Glycols - chemistry</subject><subject>Ribonucleoproteins - chemistry</subject><subject>Ribonucleoproteins - pharmacokinetics</subject><subject>RNA, Small Interfering - chemistry</subject><subject>RNA, Small Interfering - genetics</subject><subject>RNA, Small Interfering - pharmacokinetics</subject><issn>2157-846X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkNtKAzEYhIMgttQ-gDeyLxBN9s_xRihFrVAURMG7JZv8WyPbzZLdFvr2FjygVwMzzAczhFxwdsUZmOtBcCk5ZdxQVnJB-QmZllxqaoR6m5D5MHwwxrgFYbU8IxNgFpQQekr0osixTt3Ot5j6nEaMXZH86LaYiyblYnR5gyOGYojPj4siYBv3mA_n5LRx7YDzb52R17vbl-WKrp_uH5aLNe25gpECk7I22qjQWKHKgCUggiqldsFZb71xGjx3rGau0WUwoMCA1UdDs4Z5mJGbL26_q7cYPHZjdm3V57h1-VAlF6v_SRffq03aV4qDOq4_Ai7_An6bPxfAJ9PQXhw</recordid><startdate>20180501</startdate><enddate>20180501</enddate><creator>Tai, Wanyi</creator><creator>Li, Junwei</creator><creator>Corey, Eva</creator><creator>Gao, Xiaohu</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6054-0530</orcidid></search><sort><creationdate>20180501</creationdate><title>A ribonucleoprotein octamer for targeted siRNA delivery</title><author>Tai, Wanyi ; Li, Junwei ; Corey, Eva ; Gao, Xiaohu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p163t-3055b8786df9462de23ee36257ada9c9c8a73c1a0b0af72d83638397a0b70f0c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacokinetics</topic><topic>Cell Line, Tumor</topic><topic>Drug Delivery Systems - methods</topic><topic>Gene Silencing</topic><topic>Humans</topic><topic>Polyethylene Glycols - chemistry</topic><topic>Ribonucleoproteins - chemistry</topic><topic>Ribonucleoproteins - pharmacokinetics</topic><topic>RNA, Small Interfering - chemistry</topic><topic>RNA, Small Interfering - genetics</topic><topic>RNA, Small Interfering - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tai, Wanyi</creatorcontrib><creatorcontrib>Li, Junwei</creatorcontrib><creatorcontrib>Corey, Eva</creatorcontrib><creatorcontrib>Gao, Xiaohu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nature biomedical engineering</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tai, Wanyi</au><au>Li, Junwei</au><au>Corey, Eva</au><au>Gao, Xiaohu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A ribonucleoprotein octamer for targeted siRNA delivery</atitle><jtitle>Nature biomedical engineering</jtitle><addtitle>Nat Biomed Eng</addtitle><date>2018-05-01</date><risdate>2018</risdate><volume>2</volume><issue>5</issue><spage>326</spage><epage>337</epage><pages>326-337</pages><eissn>2157-846X</eissn><abstract>Hurdles in cell-specific delivery of small interfering RNA (siRNA) in vivo hinder the clinical translation of RNA interference (RNAi). A fundamental problem concerns conflicting requirements for the design of the delivery vehicles: cationic materials facilitate cargo condensation and endosomolysis, yet hinder in vivo targeting and colloidal stability. Here, we describe a self-assembled, compact (~30 nm) and biocompatible ribonucleoprotein-octamer nanoparticle that achieves endosomal destabilization and targeted delivery. The protein octamer consists of a poly(ethylene glycol) scaffold, a sterically masked endosomolytic peptide and a double-stranded RNA-binding domain, providing a discrete number of siRNA loading sites and a high siRNA payload (>30 wt%), and offering flexibility in both siRNA and targeting-ligand selection. We show that a ribonucleoprotein octamer against the polo-like kinase 1 gene and bearing a ligand that binds to prostate-specific membrane antigen leads to efficient gene silencing in prostate tumour cells in vitro and when intravenously injected in mouse models of prostate cancer. The octamer's versatile nanocarrier design should offer opportunities for the clinical translation of therapies based on intracellularly acting biologics.</abstract><cop>England</cop><pmid>30936447</pmid><doi>10.1038/s41551-018-0214-1</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-6054-0530</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | EISSN: 2157-846X |
ispartof | Nature biomedical engineering, 2018-05, Vol.2 (5), p.326-337 |
issn | 2157-846X |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6136846 |
source | MEDLINE; SpringerLink Journals |
subjects | Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacokinetics Cell Line, Tumor Drug Delivery Systems - methods Gene Silencing Humans Polyethylene Glycols - chemistry Ribonucleoproteins - chemistry Ribonucleoproteins - pharmacokinetics RNA, Small Interfering - chemistry RNA, Small Interfering - genetics RNA, Small Interfering - pharmacokinetics |
title | A ribonucleoprotein octamer for targeted siRNA delivery |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T10%3A16%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20ribonucleoprotein%20octamer%20for%20targeted%20siRNA%20delivery&rft.jtitle=Nature%20biomedical%20engineering&rft.au=Tai,%20Wanyi&rft.date=2018-05-01&rft.volume=2&rft.issue=5&rft.spage=326&rft.epage=337&rft.pages=326-337&rft.eissn=2157-846X&rft_id=info:doi/10.1038/s41551-018-0214-1&rft_dat=%3Cpubmed%3E30936447%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30936447&rfr_iscdi=true |